Form 4: Prime Medicine Director David Liu Boosts Stake with $311,955 Share Purchase

Prime Medicine, Inc. Director and 10% owner David R. Liu acquired 21,000 shares of common stock for approximately $311,955 through a pre-arranged trading plan.

Summary

• David R. Liu, a Director and 10% owner of Prime Medicine, Inc. (PRME), purchased 21,000 shares of the company's common stock.
• The transaction occurred on June 16, 2025.
• The shares were acquired at a weighted-average price of $1.4855 per share, with prices ranging from $1.46 to $1.52.
• The total value of the acquisition was approximately $311,955 (21,000 shares * $1.4855/share).
• This purchase was executed under a Rule 10b5-1 trading plan established by Mr. Liu on March 3, 2025.
• Following this transaction, Mr. Liu directly beneficially owns 20,198,945 shares of Prime Medicine, Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to an insider purchase by a significant owner and director, which typically signals confidence. The purchase being part of a 10b5-1 plan adds to the positive interpretation as it's a pre-planned investment.

Positives

• Insider buying, especially by a director and 10% owner, can signal confidence in the company's future prospects.
• The purchase was made through a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reaction to immediate market events.

Negatives

• The purchase price of $1.4855 per share is relatively low, which could indicate a depressed stock price or perceived low valuation by the insider.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the execution of a pre-planned stock purchase.

Industry Context

Insider purchases, particularly by significant shareholders and directors, are generally viewed positively as they signal confidence in the company's future. In the biotechnology or pharmaceutical sector, such purchases can be particularly noteworthy if the company is at a critical stage of development, clinical trials, or regulatory approval, suggesting the insider believes in upcoming positive catalysts. The relatively low share price at which the purchase occurred might reflect broader market sentiment towards the sector or specific company challenges, making the insider's investment a contrarian or value-oriented move.

Stakeholder Impact

• Shareholders: The purchase by a significant insider could be interpreted as a positive signal, potentially boosting investor confidence and demand for the stock.

Key Dates

Recommendation

Keywords

Prime Medicine, PRME, David R. Liu, Insider Trading, Form 4, Stock Purchase, Director, 10% Owner, Rule 10b5-1, Biotechnology, Pharmaceuticals